S.E. Kim, president and CEO at DI Biotech, the sole distributor of Gyros products in South Korea, commented: “We are extremely pleased that Binex has become the first South Korean customer to adopt this exciting new platform. Our goal at DIBiotech is to ensure that our customers have access to the latest ground-breaking technologies. We firmly believe that the Gyros platform, will not only increase productivity, but also boost the competitiveness of South Korea’s pharma and biotech companies as well as our CROs and CMOs.”
The Gyros platform is used by major biopharmaceutical companies and their service providers to improve productivity and efficiency during the development of biotherapeutics and vaccines, to boost time-critical workflows and help meet regulatory demands. The platform comprises a Gyrolab workstation, control and evaluation software and the unique microfluidic CDs in which immunoassay steps are integrated and run at nanoliter scale.
Erik Walldén, CEO at Gyros, continued, “We have been actively expanding our distributor network throughout the Asia-Pacific region and see this as a significant step on the way to establishing a global presence for our immunoassay platform.”